Contributions of p53 and PMA to γ-irradiation induced apoptosis in Jurkat cells

Hematology and Cell Therapy

Volumn 41, Issue 4, 1999, Pages 153-161

  Vigorito, E ^a   Plaza, S ^a   Mir, L ^a   Mongay, L ^a   Vinas O ^a   Serra Pages C ^a   Vives, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

irradiation; Apoptosis; p53; PKC; Transcription

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; FAS ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN KINASE C; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GAMMA IRRADIATION; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; RNA SYNTHESIS;

APOPTOSIS; GAMMA RAYS; GENE EXPRESSION REGULATION; HUMANS; JURKAT CELLS; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032887881     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-999-0153-0     Document Type: Article

References (57)

1. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10(1 1): 5772-81
2. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990;87(16):6166-70
3. Goodrich DW, Lee WH. Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53. Nature 1992;360(6400):177-9
4. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352(6333):345-7.
5. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89(10):4495-9.
6. Xiao H, Pearson A, Coulombe B, Truant R, Zhang S, Regier JL, Triezenberg SJ, Reinberg D, Flores O, Ingles CJ. Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 1994;14(10):7013-24.
7. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91(6):2230-4.
8. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Freidberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmaakers JHJ, Forrester K, Harris CC. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 1995;10(2): 188-95.
9. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70(6):923-35.
10. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70(6):937-48.
11. Oren M, Maltzman W, Levine AJ. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981;1(2):101-10.
12. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, Jr., Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1- phase checkpoint by low- oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14(9):6264-77.
13. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent GO/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10(8):934-47.
14. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 1994;84(8):2391-41 1.
15. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994;84(8):2412-21.
16. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1 992;356(6366): 2 15-21.
17. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M. Nonhereditary p53 mutations in T- cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 1994;83(10):2922-30.
18. Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, Shikano T, Ueda K, Hayashi K, Sekiya T, Hayashi Y. Mutations of the p53 and ras genes in childhood t(1 ;19)-acute lymphoblastic leukemia. Blood 1995;85(9):2546-52
19. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994;84(9):3105-12.
20. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84(9):3148-57.
21. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993 74(6):957-67.
22. Bracey TS, Miller JC, Preece A, Paraskeva C. Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10(12):2391-6.
23. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993;53(20):4776-80.
24. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994;54(14):3662-7
25. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus- mediated transfer of the wild-type p53 gene. Cancer Res 1994;54(9):2287-91.
26. Gallardo D, Drazan KE, McBride WH. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 1996;56(21):4891-3.
27. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2(10): 1665-71.
28. Ramqvist T, Magnusson KP, Wang Y, Szekely L, Klein G, Wiman KG. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 1993;8(6):1495-500.
29. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T- cell lines. Mol Cell Biol 1990;10(10):5502-9.
30. Gaya A, de la Calle O, Yague J, Alsinet E, Fernandez MD, Romero M, Fabregat V, Martorell J, Vives J. IL-4 inhibits IL-2 synthesis and IL-2-induced up-regulation of IL- 2R alpha but not IL-2R beta chain in CD4+ human T cells. Jfmmunol 1991 ;146(12):4209-14.
31. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1 979;18(24):5294-9.
32. Alberola-Ila J, Places L, Cantrell DA, Vives J, Lozano F. Intracellular events involved in CD5-induced human T cell activation and proliferation. Jfmmunol 1992;148(5): 1287-93.
33. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1 995;11(1): 199-210.
34. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998; 16(25): 3269-77.
35. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148(7) :2207-16.
36. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8(1):203-7.
37. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51(23 Pt 1):6304-11.
38. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75(4):765-78.
39. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1 995; 108(Pt 5): 1843-8.
40. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF 1, a potential mediator of p53 tumor suppression. Cell 1993;75(4):817-25.
41. Zhan Q, Bae I, Kastan MB, Fornace AJ, Jr. The p53-dependent gamma-ray response of GADD45. Cancer Res 1 994;54(1 0): 2755-60.
42. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995 ;86(5): 1903-10.
43. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9(6):1799-805.
44. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGF beta 1:a paradigm for distinct apoptotic pathways. Oncogene 1 994;9(6): 1791-8.
45. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54(8):2095-7.
46. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 1995; 11(7): 1389-94.
47. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO- 1 expression. Mol Cell Biol 1995; 15(6) : 3032-40.
48. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389(6648):300-5.
49. Tamm I, Sehgal PB. Halobenzimidazole ribosides and RNA synthesis of cells and viruses. Adv Virus Res 1978;22:187-258.
50. Chernov MV, Ramana CV, Adler VV, Stark GR. Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc Natl Acad Sci U SA 1998;95(5):2284-9.
51. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249(4971):912-5.
52. Ryan JJ, Danish R, Gottlieb CA, Clarke MF. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 1993;13(1):711-9.
53. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre- B-cell differentiation in vitro. Proc Natl Acad Sci USA 1991;88(20):8982-6.
54. Feinstein E, Gale RP, Reed J, Canaani E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 1992;7(9):1853-7.
55. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994;370(6486):220-3.
56. Whelan RD, Parker PJ. Loss of protein kinase C function induces an apoptotic response. Oncogene 1 998;16(1 5): 1939-44.
57. Khanna KK, Lavin MF. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 1993;8(12):3307-12.